Abstract A retrovirus homologue gene of cellular cyclin D 1 , walleye dermal sarcoma virus rv-cyclin gene (orf A or rv-cyclin), was expressed in the livers of zebrafish under the control of liver fatty acid-binding protein (lfabp) promoter. To prevent possible fatality caused by overexpression of the oncogene, the GAL4/upstream activation sequence (GAL4/ UAS) system was used to maintain the transgenic lines. Thus, both GAL4-activator [Tg(lfabp:GAL4)] and UASeffector [Tg(UAS:rvcyclin)] lines were generated, and the rv-cyclin gene was activated in the liver after crossing these two lines. Since no obvious neoplasia phenotypes were observed in the double-transgenic line, cancer susceptibility of the transgenic fish expressing rv-cyclin was tested by carcinogen treatment. Unexpectedly, transgenic fish expressing rv-cyclin gene (rvcyclin+) were more resistant to the carcinogen than siblings not expressing this gene (rvcyclin-). Lower incidences of multiple and malignant liver tumors were observed in rvcyclin+ than in rvcyclinfish, and the liver tumors in the rvcyclin+ group appeared later and were less malignant. These results suggest that expression of rv-cyclin protects the fish liver from carcinogen damage and delays onset of malignancy. These findings indicate that transgenic fish models are powerful systems for investigating mechanisms of inhibition and regression of liver tumors.
Introduction
Although zebrafish (Danio rerio) were the first fish shown to respond to carcinogens to cause liver neoplasia in humans (Stanton 1965) , little research has been conducted in this species until recently when intense studies of zebrafish genetics, genomics, and development have renewed interest in the use of this model for carcinogenesis research. In the past decade, a growing number of laboratories worldwide have used the zebrafish to study mechanisms of carcinogenesis and the influence of specific genes and signaling pathways in tumorigenesis (Tsai 1996; Hendricks 1996; Stern and Zon 2003) . These recent works have documented the carcinogenicity of diverse compounds administered at various developmental stages in Florida wild-type zebrafish. When treated with most carcinogens at the fry or embryo stage, zebrafish display a variety of neoplasms derived from epithelial, mesenchymal, neural, and neural crest tissues (Spitsbergen and Kent 2003; Pliss et al. 1982; Khudoley 1984; Mizgireuv et al. 2004; Hendricks 1996; Spitsbergen et al. 2000b; Spitsbergen et al. 2000a; Tsai 1996) . These data demonstrate the ease of using zebrafish to assess carcinogen responses in vivo and the capacity of zebrafish to develop a diverse range of cancers histologically similar to tumor types in humans (Goessling et al. 2007) . These experiments show that wild-type lines of zebrafish have a low incidence of spontaneous neoplasia and that wild-type and mutant lines show high rates of tumorigenesis after carcinogen treatment (Stern and Zon 2003; Goessling et al. 2007) , making them an ideal model for mechanistic carcinogenesis studies. Because of lower husbandry costs and the small body size of adults, large numbers of zebrafish can be easily housed and processed for histology, therefore large scale tumor studies are more economically feasible and offer greater statistical power than mammalian carcinogenesis studies (Stern and Zon 2003) . Moreover, fish tumors are commonly seen in the wild, and their histological characteristics resemble those of human tumors (Beckwith et al. 2000; Harshbarger and Clark 1990) , suggesting that the genetic mechanisms underlying the pathogenic changes associated with malignancy are conserved between fish and human. A comparison of human and zebrafish genome sequences demonstrates conservation of cell cycle genes, tumor suppressors, and oncogenes (Amatruda et al. 2002) . Important genes involved in human cancers, such as p53, c-myc, and angiogenesis genes also play roles in fish tumorigenesis (Patton and Zon 2001) . More recently, Lam et al. (2006) found significant molecular conservation between human and zebrafish liver tumors by comparative transcriptome analyses. The conserved expression profiles in zebrafish and human cancers provide a molecular basis for validating the zebrafish model in human disease studies.
Transgenic technology was first successfully used to model cancer in zebrafish by overexpressing the mouse oncogene c-myc specifically in lymphoid cells, resulting in T cell acute lymphoblastic leukemia (Langenau et al. 2003) . This work indicates the capability of using transgenic zebrafish as a model for cancer progression and metastases in humans and provides a new platform for drug and genetic screens in identifying modifier genes related to c-myc-induced carcinogenesis. Recently, several other transgenic zebrafish lines were developed to model specific human cancers, such as pancreatic tumors, melanoma, B cell leukemia, and precancerous conditions such as liver hyperplasia (Yang et al. 2004; Patton et al. 2005; Her et al. 2006; Sabaawy et al. 2006; Park et al. 2008) . These oncogene transgenic zebrafish demonstrate the feasibility of fish models to facilitate our understanding of oncogenesis with a potential for identifying new therapeutic targets for various cancers.
Studies of tumor induction by retroviruses and DNA viruses have led to key advances in the understanding of cell proliferation and oncogenesis and laid the foundation for modern cancer studies. Several classes of oncogenes have been identified by retroviral transduction or proviral insertion, including genes coding for tyrosine kinases (src and erbB), G proteins (ras), serine-threonine kinases (raf), growth factors (sis), and transcription factors (myc; Finney and Herrera 1995; Privalsky et al. 1984; Vennstrom et al. 1982) . Therefore, studies of retroviral oncogenes will provide important insights about the roles of proto-oncogenes in normal cell proliferation and tumor induction. Walleye dermal sarcoma virus (WDSV) is a retrovirus associated with a skin tumor termed walleye dermal sarcoma (WDS) that is endemic in walleye fish (Stizostedion vitreum) throughout North America (Bowser et al. 1988) . In contrast to other tumors induced by animal retroviruses, WDS develops and regresses seasonally. Tumors develop in the fall, increase in size until the spring, and disappear in the summer (Bowser et al. 1988; Quackenbush et al. 2001) . Therefore, this retrovirus-associated neoplastic disease in walleyes provides a dynamic model for investigating the mechanisms of oncogenesis, tumor progression, and tumor regression.
An open reading frame of WDSV, orf A, also termed rvcyclin, encodes a homologue of cellular cyclin D. The functional conservation of rv-cyclin and cyclin D has been proven by the ability of rv-cyclin to complement cell cycle progression in yeast deficient in G 1 cyclins (LaPierre et al. 1998) . Moreover, rv-cyclin has also been shown to prompt squamous epithelium hyperplasia in transgenic mice (Lairmore et al. 2000) . These observations imply that rvcyclin plays an important role in stimulating cell proliferation. However, previous studies also indicate that rv-cyclin has a function in WDS tumor regression. Rv-cyclin is expressed at low levels in developing tumors and at high levels in regressing tumors (LaPierre et al. 1998; Quackenbush et al. 1997) , consistent with a role in tumor regression. Since cyclins are involved in both tumor formation and cell death, rv-cyclin may also play a role in WDS tumor regression by inducing cell apoptosis. Therefore, investigation of the function of rv-cyclin may help us to understand the mechanisms of oncogenesis and tumor cell proliferation as well as cell death.
However, characterization of the walleye retroviruses and their putative oncogenes has been impeded by the lack of a cell culture system for viral propagation and the difficulty of working with captive wild fish . The zebrafish provides an alternative system for these studies because of their established genetics and development of transgenic technology. In this study, rvcyclin transgenic zebrafish were developed, and the function of this gene was characterized. Considering the possible fatality of rv-cyclin to the transgenic host, a GAL4/ UAS binary transgenic system was adopted to overexpress this gene. Since no increase in spontaneous tumor rate in rv-cyclin-transgenic fish was observed, 7,12-dimethylbenz [α]anthracene (DMBA) was used to treat rv-cyclintransgenic fish to examine their cancer susceptibility. Unexpectedly, we found that transgenic fish expressing rv-cyclin had significantly lower incidences of malignant liver tumor than control siblings at 7-month posttreatment. In addition, liver neoplasia developed later in rv-cyclin-transgenic fish than that in non-rv-cyclin siblings. These observations indicate that expression of rv-cyclin in zebrafish liver suppresses liver tumor formation induced by carcinogens.
Materials and Methods

Fish Maintenance
Singapore wild-type zebrafish were used for all of the experiments and maintained essentially according to the Zebrafish Book (Westerfield 1995) . Embryos were cultured in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 , 0.33 mM MgSO 4 , 0.0001% Methylene Blue) in a 28.5°C incubator until 4-5 days postfertilization (dpf). One-monthold fish were transferred to 10-L containers of the Aquatic Habitats (AHAB) recirculating system (Aquatic Ecosystems Inc., FL, USA). During the spawning period, they were kept under a diurnal cycle of 14-h light and 10-h dark.
Larvae were fed powdered Aquori Flakes staple food and brine shrimp (Aquafauna Bio-Marine, Inc. CA, USA) from 4 dpf. From 6 weeks of age, fish were fed frozen blood worms (Hikari Sales, CA, USA) and brine shrimp twice daily.
Construction of GAL4 and UAS Plasmids
For the construction of the GAL4 activator plasmid, the liver-type fatty acid binding protein gene (lfabp) promoter (2.8 kb) was amplified by polymerase chain reaction (PCR) based on Her et al. (2003) and digested by SalI/BamHI. The promoter fragment was cloned upstream of the translational start site of GAL4 (Scheer and Campos-Ortega 1999) to make pLFABP-GAL4. For the UAS effector plasmid, the UAS fragment was cut from pBlueScript (KS+)-UAS vector (Scheer and Campos-Ortega 1999) and inserted into the enhanced green fluorescent protein (EGFP) vector pEGFP1 (Clontech, CA, USA) to make pUAS-EGFP construct. Oncogene rv-cyclin (Lairmore et al. 2000) was used to replace the GFP fragment in pUAS-EGFP to make pUAS-RV-CYCLIN construct.
Microinjection and Transgenic Fish Screening
Linearized DNA at a final concentration of 150-200 ng/μL was injected into cytoplasm of zebrafish embryos at the one-cell stage. Each embryo was injected with 2.3 nL of DNA. After microinjection, the embryos were maintained in egg water in an incubator at 28.5°C. All of the injected embryos were raised to sexual maturity and screened for germline transmission. For detection of transgenic founder fish, genomic DNA from pools of F 1 embryos (24 hpf) was isolated according to Westerfield (1995) . PCR was carried out with gene-specific primers with a normal PCR program: 94°C/5 min; 30 cycles of 94°C/30 s, 58°C (variant depends on the annealing temperature of primers) per 30 s, and 72°C/1 min; followed with 72°C/10 min for extension. The F 1 embryos from transgenic founder fish were maintained to adult, and positive F 1 fish was identified with genomic DNA from fin clips.
Reverse Transcription PCR Total liver RNA was isolated by Trizol (Invitrogen, CA, USA). Qiagen OneStep RT-PCR Kits (Qiagen, MD, USA) were used for reverse transcription PCR (RT-PCR) analysis. The PCR program included reverse transcription at 50°C for 30 min, initial PCR activation at 95°C for 15 min, followed by three-step cycling: 94°C/0.5-1 min, 56-62°C/ 0.5-1 min, 72°C/1 min, for 28 to 32 cycles (GAL4, 28 cycles; rv-cyclin, 30 cycles), and a final extension at 72°C for 10 min.
Whole-Mount In Situ Hybridization and Immunohistochemical Staining
Whole-mount in situ hybridization using digoxigenin (DIG)-labeled riboprobes was carried out as previously described (Korzh et al. 1998) . The embryos were fixed with 4% paraformadehyde (PFA) in phosphate-buffered saline (PBS), hybridized with a DIG-labeled GAL4 RNA probe at 70°C, followed by incubation with anti-DIG antibody conjugated with alkaline phosphatase and by staining with the substrates, nitro blue tetrazolium and 5-bromo, 4-chloro, 3-indolyl phosphate. For immunohistochemical studies, embryos were fixed with 4% PFA/PBS, incubated with GAL4 primary antibody (sc-510, Santa Cruz, CA, USA), followed by incubation with the secondary antibody conjugated with horseradish peroxidase and by staining with diaminobenzidine solution.
DMBA Treatment
Homozygous Tg(lfabp:GAL4) was crossed with heterozygous Tg(UAS:rvcyclin). Three-week-old offspring were separated into six groups evenly for carcinogen and vehicle-control treatments. Triplicate groups of fry were treated with 0.75 ppm (milligrams per liter) of DMBA or dimethyl sulfoxide (DMSO, vehicle) for 24 h. Same groups of fry at 5-week old were treated with 1.25 ppm DMBA or DMSO again for 24 h. Treated fish were rinsed three times in fresh water and transferred into new tanks for maintenance. Treated fry were maintained in 2.5-L tanks for another month before they were transferred into 4-L tanks in the AHAB system. About 70 fish were randomly selected from each group to be maintained in each tank.
Histopathological Analysis
Whole adult fish from DMBA-treated wild-type and Tg (lfabp:GAL4;UAS:rvcyclin) fish were anesthetized, slit from heart to anus, fixed in Bouin's fixative, and embedded in paraffin. Nine sagittal step sections between the middle of the left eye and the middle of the right eye were prepared for each fish for tumor diagnosis, covering most of the organs. Sections were stained routinely with hematoxylin and eosin (H&E). Each fish was genotyped with genomic DNA from fin clips by PCR. Fisher's exact test was used to assess differences in tumor incidences between rv-cyclin transgenic fish and non-rv-cyclin siblings.
Results
Generation of Tg(lfabp:GAL4) and Tg(UAS:rvcyclin) Transgenic Lines
Of 104 founder fish developed from pLFABP-GAL4-injected embryos, five produced offspring carrying the GAL4 fragment in the genome. From 74 pUAS-RVCYCLIN-injected founder fish, two Tg(UAS:rvcyclin) lines (lines 40 and 41) were identified by genomic DNA screening.
Expression of GAL4 messenger (mRNA) in Tg(lfabp: GAL4) was detected in embryos by whole-mount in situ hybridization using a DIG-labeled GAL4 antisense RNA probe. In all of the five Tg(lfabp:GAL4) lines, GAL4 mRNA was detected specifically in the liver (Fig. 1a) . However, expression levels varied among different GAL4 activator lines. Line 8 showed the strongest expression and was selected for further experiments. Liver-specific expression of GAL4 protein in Tg(lfabp:GAL4) was also confirmed by whole-mount immunohistochemical staining using GAL4 antibody (Fig. 1b) . Thus, the GAL4 transgene was transcribed and translated properly in Tg(lfabp:GAL4).
Activation of rv-cyclin in the Livers of Adult Tg(lfabp: GAL4; UAS:rvcyclin) Fish
To test whether rv-cyclin effector gene in Tg(UAS:rvcyclin) could be activated by GAL4, Tg(lfabp:GAL4) was used to cross with Tg(UAS:rvcyclin). Liver RNA from Tg(UAS: rvcyclin) and Tg(lfabp:GAL4; UAS:rvcyclin) was used to analyze rv-cyclin gene expression. A low level of probably leaky expression of rv-cyclin in Tg(UAS:rvcyclin) was detected by RT-PCR (lanes 1-3 in Fig. 2 ). In comparison, significantly higher expression of rv-cyclin was detected in the liver of adult Tg(lfabp:GAL4; UAS:rvcyclin) (lanes 4-6 in Fig. 2) . Thus, rv-cyclin in Tg(UAS:rvcyclin) could be activated by the GAL4 protein expressed in Tg(lfabp: GAL4). In the two Tg(UAS:rvcyclin) lines, line 41 showed higher expression level; therefore, we focused on this line in subsequent experiments.
Tumorigenesis in Rv-cyclin Transgenic Zebrafish After Carcinogen Treatment
To examine the effect of rv-cyclin expression on the transgenic zebrafish, homozygous Tg(lfabp:GAL4) fish were crossed with heterozygous Tg(UAS:rvcyclin) fish. In Fig. 1 Liver-specific expression of GAL4 in Tg(lfabp:GAL4) line. a The expression of GAL4 mRNA was detected by whole-mount in situ hybridization. b GAL4 protein was detected by whole-mount immunohistochemical method. Control: sibling without GAL4 expression. Arrows indicate the liver location. Embryo stage: 4 dpf this way, ∼50% of offspring would carry both lfabp:GAL4 and UAS:rvcyclin (rvcyclin+), and the other half siblings would harbor only lfabp:GAL4 (rvcyclin-). There was no obvious increase in spontaneous tumor incidence observed in the offspring up to 1-year old. Then we tested whether rvcyclin+ double-transgenic fish were more susceptible to carcinogen treatment. DMBA, a carcinogen known to accelerate liver tumor formation in zebrafish (Spitsbergen et al. 2000a) , was used to treat the transgenic fish. Due to the lack of a screening marker to differentiate rvcyclin+ double-transgenic fish from rvcyclin-siblings, rvcyclin+ and rvcyclin-fish were maintained together and treated with DMBA (0.75 ppm at 3-week old and 1.25 ppm at 5-week old). The rvcyclin+ fish were identified by PCR from fin clip DNA. From the sixth month after exposure, some DMBA-treated fish began to show abnormal phenotypes based on gross observation, including extruded tissues, ascites, enlarged organs, ulcers, emaciation, anemia, and tumor mass. At 7-and 10-month posttreatment, all of the fish with abnormal phenotypes were collected, and 61 of them were randomly selected for histopathological examination for the presence of neoplasias. Of the 61 fish examined, 41 were found to carry the rv-cyclin oncogene, whereas only 20 were found to be rvcyclin-. Unexpectedly, of those 20 rvcyclin-fish, all (100%) were found to have neoplasia, whereas only 88% rvcyclin+ fish (36/41) had neoplasias (Fig. 3a) . The unexpected lower neoplasia incidence found in rvcyclin+ fish prompted us for further analyses for the role of rvcyclin.
DMBA-Treated Rv-cyclin Transgenic Fish Had Less Severe Liver Neoplasia than Non-rvcyclin Siblings
Liver and intestinal neoplasias were most commonly induced by DMBA in our fish. For the liver neoplasia, 51% of rvcyclin+ fish (21/41) and 45% of rvcyclin-fish (9/20) developed liver neoplasia (Fig. 3a) . However, livers in DMBA-treated rvcyclin-fish were more severely affected than those in DMBA-treated rvcyclin+ fish. Severity was classified according to the number of liver neoplasias per fish and incidence of malignancy. As shown in Fig. 3b , rvcyclin+ fish had a lower incidence of multiple liver neoplasias and a higher incidence of single liver neoplasia. Eight out of 20 rvcyclin-fish (40%) had malignant liver neoplasias, whereas only 11 out of 41 rvcyclin+ fish (27%) had malignant liver neoplasias (Fig. 3c) . Furthermore, the incidence of benign liver neoplasias was higher in rvcyclin+ than in rvcyclinfish (Fig. 3c) , again indicating that the liver neoplasias were less severe in rvcyclin+ than in rvcyclin-fish.
We also compared the distributions of liver neoplasia type in the rvcyclin+ and rvcyclin-fish. As shown in Fig. 3d , hepatocellular adenoma, a benign liver cancer (Fig. 4a) , constituted more than 30% of the neoplasias in rvcyclin+ fish but only 21% in rvcyclin-fish. In rvcyclinfish, most of liver neoplasias were malignant, including hepatocellular carcinoma (29%) and cholangiocellular carcinoma (29%; Fig. 4b, c) . In total, 31 liver neoplasias were found in rvcyclin+ fish, 18 (58%) of which were malignant. In rvcyclin-fish, however, 11 out of the 14 (79%) liver neoplasias were malignant, a much higher incidence than that in rvcyclin+ fish. This result was unexpected and contradictory to our original hypothesis that the transgenic fish expressing rv-cyclin in the liver would be more susceptible to the carcinogen and show more malignant liver neoplasias than rvcyclin-fish. These data further confirm that liver neoplasia in rvcyclin-fish is more severe than in rvcyclin+ fish, suggesting that expression of the oncogene rv-cyclin in the liver may protect or compensate for the damage caused by DMBA.
In addition, there was also a high incidence of intestinal neoplasia in DMBA-treated rvcyclin+ fish (Fig. 3a) ; all of which were malignant in both rvcyclin+ and rvcyclin-fish. To investigate the possible effect of rv-cyclin expression on the intestinal and liver neoplasia, we examined the rv-cyclin mRNA expression in the intestines of adult Tg(lfabp:GAL4; UAS:rvcyclin) fish. Weak expression of rv-cyclin from UAS:rvcyclin was detected in the intestines, but it was comparable to that of the leaky expression in the Tg(UAS: rvcyclin) fish (data not shown). Thus, the contribution of rv-cyclin expression to intestinal neoplasia was not obvious, and there was also little difference in neoplasia incidence between rvcyclin+ and rvcyclin-.
Liver Neoplasia Developed Later in DMBA-Treated Rvcyclin+ Transgenic Fish Than That in RvcyclinSiblings
Since cancer occurrence and growth may be related to aging (Hasty and Vijg 2002) , we also investigated whether Fig. 2 Activation of rv-cyclin in adult livers in Tg(lfabp:GAL4; UAS: rvcyclin line 41) fish as compared with Tg(UAS:rvcyclin) line 41. Lanes 1-3, three adult fish livers from Tg(UAS:rvcyclin); lanes 4-6, three adult fish livers from Tg(lfabp:GAL4; UAS:rvcyclin) the liver cancer incidence and severity could be affected by the age of fish. Fish samples were collected at 7 and 10 months after treatment and kept in two groups according to the sampling time.
Liver neoplasia incidence at these two time points is shown in Fig. 5a . At 7-month posttreatment, 34 fish of abnormal phenotype were sampled, of which 19 were identified as rvcyclin+ and 15 were rvcyclin-. Of the rvcyclin-fish, 53% had liver neoplasia, whereas only 32% of rvcyclin+ fish had liver neoplasia. At 10-month posttreatment, 27 abnormal fish were sampled, 22 rvcyclin+ and five rvcyclin-. Of these, 68% of the rvcyclin+ fish and 20% of the rvcyclin-fish developed liver neoplasia. This observation indicates that liver neoplasia developed earlier in rvcyclin-fish than in rvcyclin+ fish.
Neoplasm severity was also analyzed at the two time points. At 7-month posttreatment (Fig. 5b) , the incidence of malignant liver neoplasia in rvcyclin-was significantly higher than that in rvcyclin+ (p<0.05) by Fisher's exact test; in fact, all of the liver neoplasias in the rvcyclin-fish were malignant. In contrast, at 10-month posttreatment, the incidence of malignancy with rvcyclin+ was higher than with rvcyclin-, and all of the liver neoplasias from rvcyclin-fish were benign. These results further confirmed that the malignant liver neoplasia appeared earlier in rvcyclin-than in rvcyclin+.
We also compared the severity of neoplasia in other organs or tissues at these two stages, such as intestinal and lymphoid cells, but no significant differences were found between rvcyclin+ and rvcyclin-fish (data not shown).
Our data indicate that the expression of oncogene rvcyclin in the liver negatively affected progression of liver neoplasias. Since rvcyclin-control fish were more sensitive to DMBA in the induction of liver neoplasia at a younger , and a higher rate of benign tumors (HA, BA, MA) than rvcyclin-fish. HCC hepatocellular carcinoma, BC biliary carcinoma/cholangiocellular carcinoma, MC mixed carcinoma with hepatocellular and biliary components, HB hepatoblastoma, LMSA leiomyosarcoma, MM intestinal differentiation in liver tumors with differentiation into malignant enterocytes and malignant smooth muscle, HA hepatocellular adenoma, BA biliary adenoma/cholangiocellular adenoma, and MA mixed adenoma with hepatocellular and biliary components age than were rvcyclin+ fish, the expression of rv-cyclin may play a role in protecting the liver from damage caused by DMBA.
More Rvcyclin+ Transgenic Fish Survived After the DMBA Treatment than Rvcyclin-Siblings To further investigate the protective effect of the rv-cyclin gene on DMBA-treated transgenic fish, the percentage of rvcyclin+ and rvcyclin-fish in the total number of surviving Tg(lfabp:GAL4;UAS:rvcyclin) fish (including all of the fish sampled and 61 fish diagnosed) was analyzed. All of the surviving DMBA-treated fish were sacrificed, and rvcyclin+ fish were identified by PCR. Since heterozygous Tg(UAS:rvcyclin) fish were used to cross with homozygous Tg(lfabp:GAL4) fish, the numbers of rvcyclin+ and rvcyclin-were expected to be approximately equal. In the sampled DMSO-treated control group (n=116), rvcyclin+ fish accounted for 49% and rvcyclin-fish accounted for 51% of those that survived (Fig. 6) . These similar percentages indicate that the rv-cyclin transgene did not affect survival rate. However, in the DMBA-treated group (n=160), 65% of surviving fish were rvcyclin+, and only 35% were rvcyclin-fish (Fig. 6 ). The significant difference (p<0.01 by Chi-square test) between DMBA-and DMSO-treated groups suggests that DMBA had more effect on the survival of rvcyclin-fish. This result confirms that rvcyclin+ fish were more resistant to the general toxicity of DMBA.
Discussion
In this study, we generated stable GAL4/UAS transgenic zebrafish lines to evaluate the function of rv-cyclin and found that expression of rv-cyclin in the liver resulted in Recently, in a separate study, both WDSV orfA (named rvcyclin in this study) and orfB have been expressed in transgenic zebrafish under a ubiquitous promoter. Consistent with our observations, no increase of tumor incidents was found from these transgenic lines (Paul et al. to be published separately). We hypothesize that rv-cyclin protects against damage induced by DMBA. Since neoplasm severity in liver, but not in other organs, showed great differences between rvcyclin+ and rvcyclin-fish, liverspecific expression of rv-cyclin is the probable cause of this difference. This effect on liver might decrease mortality induced by carcinogen treatment (Fig. 6) . The mechanism of rv-cyclin protection of the liver from tumor formation may be inferred from the following facts.
Firstly, WDSV is a retrovirus associated with seasonal neoplasia development and regression. While the mechanism of regression is not clear, analyses of regressing tumors in the spring have shown a type of cell death morphologically consistent with apoptosis (Martineau et al. 1990 ). The rv-cyclin gene encodes a cyclin D homolog (LaPierre et al. 1998) , and high levels of human cyclin D have been observed in tissue culture cells undergoing apoptosis (Fukami et al. 1995; Janicke et al. 1996) . Since high levels of rv-cyclin transcripts have been observed in spring tumors (LaPierre et al. 1998; Poulet et al. 1996) , it is possible that it plays a role in tumor regression by inducing apoptosis.
In addition, expression of rv-cyclin protein inhibited cell growth and/or caused cell death in fish and mammalian cells; the first 49 N-terminal residues of rv-cyclin were sufficient to cause these effects (Zhang and Martineau 1999) . However, BLAST search found that the N-terminal of rv-cyclin is more conserved to that of cyclin A than that of cyclin D (Zhang and Martineau 1999) . Interestingly, high expression of cyclin A was found to be associated not only with cancer formation (Brechot 1993) but also with apoptosis depending on the physiological context (Hoang et al. 1994; Sozmen et al. 2009 ). Therefore, rv-cyclin might also arrest the cell cycle and/or cause apoptosis, in addition to causing cell proliferation, as demonstrated by LaPierre et al. (1998) . In our transgenic fish expressing rv-cyclin, it is possible that this gene played stronger roles in cell apoptosis or cell cycle arrest than in cell proliferation so that the liver in rvcyclin+ fish was more resistant to DMBA-induced oncogenesis. As a result, fewer malignant tumors and lower tumor multiplicity developed in the livers of rvcyclin+ transgenic fish.
Expression of rv-cyclin protein inhibits eukaryotic promoters, including carp β-actin promoter, WDSV-LTR (long terminal repeat), CMV immediate early promoter, SV40 early promoter, and MMTV full-length LTR (Zhang and Martineau 1999) . Rv-cyclin activates the WDSV promoter but suppresses the SV40 promoter in the same Fig. 6 Percentages of rvcyclin+ and rvcyclin-fish in total numbers of surviving fish after DMSO or DMBA treatment Fig. 5 Liver neoplasia at 7-and 10-month posttreatment in DMBAtreated rvcyclin+ and rvcyclin-transgenic fish. a Comparison of total liver neoplasia incidence at 7-and 10-month posttreatment. b Comparison of malignant/benign liver tumor incidence at 7-and 10-month posttreatment mammalian cells, indicating that rv-cyclin either enhances or inhibits transcription from different promoters in the same cell type (Rovnak and Quackenbush 2002) . In addition, rv-cyclin is also capable of enhancing or inhibiting the same promoter in different cell types (Rovnak and Quackenbush 2002 ). These observations demonstrate that the effect of rv-cyclin protein on transcriptional regulation is dependent on both the promoter and the cell type. Therefore, it is possible that the expression of rv-cyclin protein in the liver of our transgenic fish inhibited cancer formation by inhibiting oncogenes and/or activating tumorsuppressor genes.
Moreover, rv-cyclin protein is colocalized with RNA polymerase II, cyclin-dependent kinase 8 (Cdk8, the kinase partner of cyclin C), some splicing factors, and several transcription factors Rovnak and Quackenbush 2002) . These factors form a complex required for transcription and mRNA processing. Due to the structural and functional homology of rv-cyclin with cellular cyclins (LaPierre et al. 1998; Lairmore et al. 2000) , rv-cyclin expressed in our rv-cyclin transgenic fish might bind with Cdk8 and form a new complex which may change the activity and/or specificity and decrease transcription (Rovnak and Quackenbush 2002) .
The interesting observations from our transgenic fish may be applied to the study of mammalian liver cancer induced by carcinogens. This transgenic model will be a useful tool in the study of cancer inhibition and regression. However, more experiments will be needed to investigate the mechanism of the negative effect of rv-cyclin gene on carcinogen-induced liver tumor formation.
